41 Background: Medications for opioid use disorder (MOUD) and alcohol use disorder (MAUD) are effective 42 and under-prescribed. Hospital-based addiction consult services can engage out-of-treatment adults in 43 addictions care. Understanding which patients are most likely to initiate MOUD and MAUD can inform 44 interventions and deepen understanding of hospitals' role addressing substance use disorders (SUD). 45 46 Objective: Determine patient-and consult-service level characteristics associated with MOUD/MAUD 47 underscoring the need to provide hospital-based addictions care as a health-system strategy. 64 Methamphetamine's negative association with MOUD/MAUD warrants further study. 65 66 67
initiation during hospitalization 48 49 Methods: We analyzed data from a study of the Improving Addiction Care Team (IMPACT), an 50 interprofessional hospital-based addiction consult service at an academic medical center. Researchers 51 collected patient surveys and clinical data from September 2015 to May 2018. We used logistic 52 regression to identify characteristics associated with medication initiation among participants with OUD, 53 AUD, or both. Candidate variables included patient demographics, social determinants, and treatment-54 related factors. 55 56 Results: 339 participants had moderate to severe OUD, AUD, or both and were not engaged in 57 MOUD/MAUD care at admission. Past methadone maintenance treatment (aOR 2.07, 95%CI (1.17, 58 3.66)), homelessness (aOR 2.63, 95%CI (1.52, 4.53)), and partner substance use (aOR 2.05, 95%CI (1.12, 59 3.76) were associated with MOUD/MAUD initiation. Concurrent methamphetamine use disorder (aOR 60 0.32, 95%CI (0.18, 0.56)) was negatively associated with MOUD/MAUD initiation. 61
Conclusions:
The association of MOUD/MAUD initiation with homelessness and partner substance use 62 suggests that hospitalization may be an opportunity to reach highly-vulnerable people, further
INTRODUCTION 68
Hospitalization can be a reachable moment to initiate care for people with substance use disorders 69 (SUD) (Englander et al., 2017) . Many people with SUD who are admitted to general medical hospitals are 70 not engaged in treatment and they do not come to the hospital seeking addictions care (Englander et (Rastegar et 82 al., 2016) . Further, hospitalization is a high-risk touchpoint after which people with opioid use disorder 83 are at increased risk for overdose and death. A recent study in Massachusetts found that hospitalization 84 for injection-related infection was associated with a 54-fold increase in mortality, and that MOUD can 85 mitigate this risk (Larochelle et al., 2019) . Medication, combined with psychosocial interventions, 86 comprise first line treatment for moderate to severe alcohol use disorder. MAUD is associated with 87 reduced drinking days, reduced alcohol consumption, and increased abstinence from alcohol (Jonas et 88 al., 2014) . Despite their effectiveness, less than 10% of people with alcohol use disorder receive MAUD 89
(Substance Abuse and Mental Health Services Administration, 2017) and only 20%-40% of people with 90
OUDs are receiving life-saving medication treatment (Jones et al., 2015) . 91 Nationally, hospital-based addiction medicine consult services are emerging as a way to engage out-of-93 treatment adults in addictions care (Priest and McCarty, 2019) . A study at a Boston academic medical 94 center found that 30% of patients with high risk alcohol and drug use were engaged in treatment prior 95 to admission, and that hospital addiction consultation was associated with increased treatment 96 engagement after discharge (Wakeman et al., 2017) . In a study of Oregon Medicaid recipients 97 comparing adults seen by our addiction consult service to matched controls, we found that 17% of 98 patients were engaged in treatment prior to hospitalization. Treatment engagement increased to 39% in 99 the 34 days after discharge among patients seen by our addiction consult service, compared to 23% 100 
Setting and study design: 112
We analyzed survey data collected as part of a study of the Improving Addiction Care Team (IMPACT) at 113 an urban, academic medical center in Portland, Oregon. IMPACT is a hospital-based addiction consult service that includes care from addiction medicine providers (physicians or advance-practice providers 115 (APPs)), social workers, and peers with lived experience in recovery (Englander et Finally, research team members abstracted data from electronic medical records. 151
Measures: 152
We selected potential covariates based on a priori hypotheses and face validity. 153
Covariates from the patient survey included gender (male/female), race (American Indian/Alaska Native, 154
Asian, African American/Black, Native Hawaiian/other Pacific Islander, white, more than one race, 155 refused), income in the previous year ($10,000 increments, $0 to >$50,000), housing status 156 (housed/unhoused), partner with substance use (yes/no), rural home zip code (yes/no), history of past 157 but not current methadone maintenance engagement (yes/no) and access to a usual primary care clinic 158 (yes/no). We identified rural zip codes using the Federal Office of Rural Health Policy designated rural zip 159 codes (Health Resources & Services Administration, 2018). We determined past but not current methadone maintenance therapy using the Addiction Severity Index Lite (ASI-lite) measurement tool; 161 and considered patients who identified past methadone maintenance therapy without use in the last 30 162 days (Cacciola et al., 2007) . Covariates from the case closure form included opioid use disorder (yes/no), 163 alcohol use disorder (yes/no), methamphetamine use disorder (yes/no), peer support delivered in 164 hospital (yes/no). Discussion with members of the clinical and research team suggested that cocaine and 165 benzodiazepine use would be very low in our population; hence, we did not consider these covariates in 166 our research. Covariates from chart review included patient age (years), insurance status (any Oregon 167
Medicaid, Medicare, other), and number of IMPACT clinician and social worker visits per day 168 (continuous). 169
Our outcome measure was in-hospital initiation of MOUD, MAUD, or both, and was determined from 170 case closure forms and validated via chart review. MOUD included the three FDA-approved medications 171 for opioid use disorder: methadone, buprenorphine (including buprenorphine-naloxone), and 172 naltrexone. MAUD included naltrexone, acamprosate, disulfiram, and gabapentin. We included 173 gabapentin only if it was prescribed for treatment of alcohol use disorder. We elected to include 174 gabapentin even though it is a not FDA approved for treatment of AUD because in hospitalized adults 175 with AUD and acute pain on opioids who are reluctant to take multiple three-time daily medication, it 176 can be the best alternative for MAUD. We felt including it was better reflective of MAUD initiation than 177 excluding it. We excluded all medications if there was no plan to continue after hospital discharge; for 178 example, methadone for withdrawal only with no plan for methadone maintenance post-discharge. 179
Covariate manipulation 180
We reclassified race as Caucasian/non-Caucasian because of sample size among non-Caucasian patients; 181
we included patients who did not know their race, were missing race information or refused to answer as Caucasian. One participant was transgender; we reclassified this person the gender they identify with. 183
If participants were unsure if they had any income in the previous year, we classified them as no income. 184
Finally, we created a "dose indicator" for IMPACT delivery, defined as the total number of documented 185 IMPACT provider or social worker encounters during hospitalization, divided by the total number of 186 hospital days. We dichotomized this as a binary covariate (at least 1 visit per day/less than 1 visit per 187 day). We report this variable in our table but did not consider this for inclusion in our analyses, as it may 188 be challenging to interpret without a measure of patient motivation for treatment and could represent 189 confounding by indication. 190
We were concerned that medication initiation would differ significantly by diagnosis (AUD, OUD or 191 both). We chose to include an interaction term to determine if IMPACT delivery differed by diagnosis; if 192 the interaction term was significant, we planned to present the terms separately in the paper. 193
194

Data analysis 195
Primary analysis and fit 196
We built a logistic regression model to estimate the relationship of baseline participant characteristics 197 with the binary outcome variable MOUD and/or MAUD initiation. We fit our logistic regression model 198 using a conservative estimated covariate ratio of 10 events per degree of freedom (Cacciola et al., 2007) . 199
We used backwards stepwise elimination with a relaxed p-value of 0.20 to finalize our model and did not 200 force any covariates into our model. We evaluated our continuous covariates for linearity in the log-201 odds using Lowess scatter plot (comparing medication intention and continuous covariates individually 202 and evaluated all covariates for collinearity using a correlation matrix). Finally, we used a Lemeshow test to evaluate model goodness-of-fit (Hosmer and Lemeshow, 2000) .
For patients who were admitted more than once, we used only the first encounter to both comply with 205 the assumption of independence in logistic regression testing and because we were primarily interested 206 in associations with MOUD/MAUD initiation following a first encounter with IMPACT. We did not adjust 207 for multiple comparisons in this exploratory study. 208
Missing Data 209
We anticipated minimal missingness in surveys conducted in the hospital, and so only included patients 210 with complete covariate data, other than as listed in data manipulations above (Figure) . 211
Sensitivity analysis 212
We conducted two sensitivity analyses. First, we identified influential observations using Pregibon's 213
Delta-Beta statistic. Observations with a Delta-Beta statistic greater than 0.20 were removed. Second, 214
we re-ran our analyses without imputing Caucasian when race was missing. We planned to report 215 results alongside the primary analysis if directionality or significance of any covariate changed. 216
RESULTS 217
During the study period, 760 patients were referred to IMPACT. Researchers approached 689 patients, 218
and 486 consented to participate in surveying. Of those, 401 had moderate to severe OUD and/or AUD 219 and 349 had no pharmacotherapy for OUD/AUD before admission (Figure) . Two patients were identified 220 as in "sustained remission" from both alcohol and opioid use and were excluded. One patient died in the 221 hospital. 346 participants were eligible for inclusion in the model. Of those, 248 (71.7%) initiated 222 MOUD/MAUD during hospitalization. Study participants were predominantly Caucasian (80.9%), had 223 opioid use disorder without alcohol use disorder (52.0%), were experiencing homelessness (55.0%), had 224
Medicaid insurance (76.3%), and had an established primary care clinic (61.3%). 30.0% of participants 225 had a co-occurring moderate or severe methamphetamine use disorder (Table 1) . 226
In our analysis, past methadone maintenance treatment initiation (aOR 2.24, 95%CI (1.28, 3.94)), 227 homelessness (aOR 2.52, 95%CI (1.47, 4.30)), and having a partner with substance use (aOR 2.06, 95%CI 228 (1.13, 3.74were associated with MOUD/ MAUD initiation. Concurrent methamphetamine use disorder 229 (aOR 0.32, 95%CI (0.18, 0.56)) was negatively associated with MOUD/MAUD initiation (Table 2) . In 230 addition to these covariates, backwards selection also included age and gender in our final model, 231 though they are not statistically significant. Neither sensitivity analysis changed the direction or 232 significance of results. The interaction term evaluating if the IMPACT dose indicator varied by diagnosis 233 (AUD only vs any OUD) was not significant, and was not included in the final model (p=0.97). 234
Among participants with any OUD (n=219), methadone was the most common MOUD (n=80; 36.5%), 235 followed by buprenorphine (n=62, 28.3%). Eight participants with OUD (3.7%) received intramuscular 236 naltrexone. Among participants with any AUD (n=166), 41 (24.7%) received any naltrexone (oral or 237 intramuscular), and 39 (23.5%) received acamprosate (Table 3) . 238
Discussion 239
Our study identifies predictors of MOUD and/or MAUD initiation among hospitalized adults seen by an 240 addiction consult service. We found that current homelessness or a partner with substance use 241 predicted MOUD/MAUD initiation. Co-occurring methamphetamine use disorder, however, was 2018). Previous studies in community settings found that having a partner with substance use is 261 associated with lower readiness to engage in treatment (Riehman et al., 2000) . By contrast, our study 262 found increased rates of MOUD/MAUD initiation in this population. Though we do not have data to 263 explain this unexpected finding, we speculate that there may be an important interplay between 264 motivation to initiate treatment and barriers to care. Specifically, patients with fewer barriers who are 265 motivated to initiate treatment may do so prior to hospitalization. Our findings suggest that 266 hospitalization may serve as an opportunity to engage hard-to-reach populations. 267
The finding that co-occurring methamphetamine use disorder is negatively associated with MOUD/ 268 Little is known about the association of methamphetamine use and treatment with medications for 274 opioid and alcohol use in general, and specifically among hospitalized adults. However, our research is 275 consistent with earlier work in community settings. One study of clients with opioid and 276 methamphetamine use who accessed services across 17 Washington State syringe exchanges found that 277 recent methamphetamine use was negatively associated with interest in getting help for OUD 278 (AOR = 0.49; 95% CI: 0.26, 0.91) (Frost et al., 2018) . Another primary care based study among people 279 with OUD and recent stimulant use found that clinic policies eliminating the requirement for stimulant 280 abstinence were associated with higher rates of buprenorphine initiation, but also with lower 281 buprenorphine treatment retention (Payne et al., 2019) . 282
The negative association of methamphetamine use with MOUD/MAUD initiation warrants further 283 exploration, and could be due to a variety of system-, provider-, or patient-factors. We speculate that 284 patients with methamphetamine use may perceive their alcohol and/or opioid use as secondary and not 285 needing MOUD/MAUD or that methamphetamine withdrawal, cravings, or psychiatric symptoms may 286 interfere with patients or providers' ability to initiate MOUD/MAUD. It is also possible that community 287 SUD treatment policies influence patients' decisions about MOUD/MAUD, as methadone and 288 buprenorphine treatment programs commonly dismiss patients if their urine drug screens result positive 289 for methamphetamine. Though unknown, it is also possible that methamphetamine use is a marker for 290 social marginalization or other factors that might make people less likely to initiate MOUD/MAUD. Co-291 use of methamphetamines and opioids is increasingly common due to synergistic euphoric or balancing 292 effects; easier access to methamphetamine; social pressures to co-use; and co-use as a marker for more 293 severe SUD (Ellis et al., 2018) . How these factors effect non-treatment seeking, hospitalized adults 294 remains unclear. 295
This study has several limitations. It is a single-site study and all patients received care from an addiction 296 consult service. Findings may not be transferable to settings without a consult service or where the 297 consult service is comprised of different team members or has different activities. Second, not all 298 IMPACT patients agreed to participate in the survey. It is possible that people who participated were 299 more or less likely to initiate MOUD/MAUD. Further, this study took place in Oregon and participants 300 had low racial and ethnic diversity. Additionally, we asked patients about past methadone use because 301 this is included in the ASI-lite, but we did not ask about other past MOUD or MAUD exposure. 302
Associations between all types of past MOUD/MAUD treatment may be important to test in predicting 303 hospital MOUD/MAUD in future studies. Further, our analysis not adjust for multiple comparisons as the 304 nature of this work was exploratory. Additionally, we looked only at the association of MOUD/MAUD 305 initiation following a first encounter with IMPACT. Future research should explore effects of repeated 306 exposure to addiction consult services for individuals who are readmitted to hospitals and have repeat 307 addiction consultation. Future studies should also explore additional patient-and consult-service factors 308 that promote MOUD/MAUD initiation such as patient readiness to change. This analysis included all 309 participants regardless of AMA discharge. Our hypothesis is that AMA discharge would be strongly 310 predictive of not initiating MOUD/MAUD with a plan to continue; future studies could explore this more 311 closely. Finally, while important, medication initiation does not reflect long-term treatment 312 engagement. Future studies of treatment engagement and retention specific to MOUD/MAUD will be 313 important. 314
315
Our study has several important implications for clinical care and research. First, the findings that 316 homelessness and having a partner with substance use was positively associated with MOUD/MAUD 317 initiation suggests that these vulnerable people may not be accessing treatment outside of the hospital. 318
It also supports the potential value of an interprofessional hospital-based addictions team with 319 resources dedicated to addressing social factors that may influence treatment retention after discharge. 320
For IMPACT, this includes social workers and peers who work to connect people with housing, engage 321 partners in addictions care, develop relapse prevention plans, and tailor post hospital treatment plans to 322 support retention in care. Our findings also have implications for community treatment, highlighting the 323 importance of addressing social determinants of health across the continuum of hospital and 324 community SUD to support treatment engagement and retention. 325
The fact that methamphetamine use is associated with lower MOUD/MAUD initiation is important, 326 especially as we consider drivers for the opioid overdose crisis. Most opioid overdose deaths involve 327 multiple substances (Barocas et al., 2019) and initiation of MOUD during acute care encounters is critical 328 to overdose prevention (Larochelle et al., 2018) . Our findings suggest the need for further research to 329 explore the association of methamphetamine use and MOUD, MAUD, and hospital-based addiction 330 medicine care. Future studies should also examine effect of MOUD/MAUD initiation during 331 hospitalization on pertinent clinical outcomes including substance use, long-term SUD treatment 332 engagement, healthcare utilization, quality of life, overdose risks, and other health outcomes. 333
